Multi-Gene Pharmacogenomic Testing in a Community-Based Setting Is Feasible and Reduces Total Healthcare Costs.

ABSTRACT: Pharmacogenomic (PGx) testing using multi-gene panels (mgPGx) is documented to improve clinical outcomes; however, real-world data on its economic impact remain limited. This study aimed to evaluate the utility and economic value of mgPGx testing among Medicare patients within a community-based health system. We identified Medicare Advantage patients within the primary care setting of a community-based health system hospital who were taking ≥ 1 PGx-guided medication using a stratification algorithm. In total, 1042 patients participated in mgPGx testing. We evaluated the prevalence of PGx medications, polypharmacy involving PGx medications, and actionable results (i.e., a phenotype with PGx guidance and a relevant PGx medication). A Total Cost of Care (TCOC) analysis was performed for a sub

SUBMITTER: El Rouby N 

PROVIDER: S-EPMC12658616 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature